Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New device zaps nerves and plays sounds to quiet tinnitus

NCT ID NCT07548320

Symptom relief Sponsor: Neurive Co.,Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a device called Soricle that combines mild nerve stimulation with sound to help people with tinnitus, a condition where you hear ringing or noise in your ears. 36 adults with subjective tinnitus used the device daily for 8 weeks. The goal was to see if it reduces tinnitus symptoms and is safe to use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

36 people

The number who actually took part.

Started

Mar 2025

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older * Patients with subjective tinnitus * Able to understand and provide informed consent * Willing to comply with study procedures Exclusion Criteria: * Objective tinnitus * Severe hearing loss requiring immediate treatment * History of neurological or psychiatric disorders that may affect study outcomes * Use of other tinnitus treatments during the study period * Any condition that, in the investigator's judgment, may interfere with study participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Subjective tinnitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

tinnitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Subjective tinnitus Tinnitus

Contacts and locations

Locations

  • Korea University Guro Hospital

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.